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Migration toward pathology is the first critical step in stem cell
engagement during regeneration. Neural stem cells (NSCs) migrate
through the parenchyma along nonstereotypical routes in a precise
directed manner across great distances to injury sites in the CNS,
where they might engage niches harboring local transiently ex-
pressed reparative signals. The molecular mechanisms for NSC
mobilization have not been identified. Because NSCs seem to home
similarly to pathologic sites derived from disparate etiologies, we
hypothesized that the inflammatory response itself, a character-
istic common to all, guides the behavior of potentially reparative
cells. As proof of concept, we show that human NSCs migrate in
vivo (including from the contralateral hemisphere) toward an
infarcted area (a representative CNS injury), where local astrocytes
and endothelium up-regulate the inflammatory chemoattractant
stromal cell-derived factor 1 (SDF-1). NSCs express CXC chemo-
kine receptor 4 (CXCR4), the cognate receptor for SDF-1. Exposure
of SDF-1 to quiescent NSCs enhances proliferation, promotes
chain migration and transmigration, and activates intracellular
molecular pathways mediating engagement. CXCR4 blockade ab-
rogates their pathology-directed chain migration, a developmen-
tally relevant mode of tangential migration that, if recapitulated,
could explain homing along nonstereotypical paths. Our data
implicate SDF-1CXCR4, representative of the inflammatory mi-
lieu characterizing many pathologies, as a pathway that activates
NSC molecular programs during injury and suggest that inflam-
mation may be viewed not simply as playing an adverse role but
also as providing stimuli that recruit cells with a regenerative
homeostasis-promoting capacity. CXCR4 expression within germi-
nal zones suggests that NSC homing after injury and migration
during development may invoke similar mechanisms.
human stem cells  homing  chain migration  stroke  hypoxia–ischemia
Neural stem cells (NSCs), both mouse and human, have acapacity for precise migration to even widespread and distant
areas of pathology in a number of experimental models of CNS
disease, including at ages where extensive migration has conven-
tionally been deemed to be limited (1–6). It is both intriguing and
perplexing to recognize, however, that NSCs seem to home simi-
larly to pathologic sites derived from disparate etiologies. Because
stem cell engagement with a degenerating environment (and niches
harboring transiently recapitulated local reparative signals) (5, 7) is
the first critical step in regeneration, realizing the therapeutic
promise of the NSC depends in part on understanding the mech-
anisms underlying its mobilization during injury. For such precise
homing over long distances and nonstereotypical routes to occur,
we judged that signals must be generated at the site of pathology.
One of the few characteristics that these otherwise disparate
pathologies had in common was an inflammatory signature. We
hypothesized that the inflammatory response itself might guide the
behavior of potentially reparative cells. Becausewe have shown that
NSCs preferentially home to the site of experimental stroke (3, 4),
even if transplanted far from the infarct, and because this model
provides a clearly defined pathological region with precise initia-
tion, as proof of concept we used this paradigm to investigate
whether products of inflammation, e.g., chemokines, might be good
candidates for injury-initiated signals to which human NSCs
(hNSCs) respond.
Materials and Methods
NSC Isolation and Culture. We used several NSC lines (n  5),
including bFGF-dependent human and mouse NSCs, isolated and
maintained as described (8–11) (see Supporting Text, which is
published as supporting information on the PNAS web site).
Migration Assays. The number of cells crossing a fibronectin-coated
8-m pore membrane when confronted with varying concentra-
tions of stromal cell-derived factor 1 (SDF-1) in a Boyden
chamber was interpreted to represent their migratory capacity;
chain migration was observed by direct microscopy (both detailed
in Supporting Text).
Induction of Hypoxic–Ischemic (HI) Cerebral Injury. As detailed in
Supporting Text, HI was induced by the Vannucci method (4). For
organotypic explants, adult C57BL6 mice were subjected to left
middle cerebral artery occlusion as described (12) and the brains
harvested after 5 days for migration assays under confocal micros-
copy (seeSupporting Text); slice cultures from the right nonischemic
hemisphere served as controls for the left ischemic ones.
hNSC Transplantation. hNSCs, prelabeled ex vivo with nondiffus-
ible fluorescent cell tracker (CM-DiI, Cell Tracker, Molecular
Probes) were transplanted 3 days after induction of HI into the
infarcted hemisphere of each mouse brain or into the contralat-
eral hemisphere, as described (4), and the brains processed 2, 7,
and 10 weeks later under confocal microscopy, as detailed in
Supporting Text.
Statistical Analysis. Statistical analysis was performed by using the
paired Student t test. For migratory analysis, a test for repeated-
measures ANOVA with Bonferroni correction for multiple
comparisons was used. P  0.05 was considered significant.
Results
Proliferation of self-renewing multipotent hNSCs in bFGF (6, 8,
9) is enhanced after incubation with increasing doses of recom-
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binant human SDF-1 (hSDF-1) (Fig. 1a). Furthermore, hNSC
transmigration through a fibronectin-coated Boyden chamber
membrane (Fig. 1b) to a chemotactic gradient of hSDF-1 is
dose-dependent. During development and in some CNS regions,
NSCs normally undergo a unique form of tangential migration
called chain migration (13, 14), in which neural cells slide and
glide along each other, using each other for guidance [e.g., Fig.
6 a and b (arrows), which is published as supporting information
on the PNAS web site]. The use of such a mechanism by
migrating NSCs in response to injury might explain how patho-
logical regions can be targeted and reached by NSCs even when
they are not positioned along stereotypical migratory paths. To
investigate a potential role for SDF-1 in promoting andor
directing chain migration, bFGF-perpetuated hNSC neuro-
spheres (n  125) were seeded onto a fibronectin substrate. In
the absence of factors such as bFGF or leukemia-inhibiting
factor, hNSCs formed few migratory chains after 6 days in
culture (Fig. 6c). However, the addition of SDF-1 induced a
significant increase in the number and density of chains of cells
emanating from the neurospheres (Fig. 6 d and e). SDF-1 alone
was sufficient to increase migratory parameters significantly
(Fig. 1 c and d). The combination of SDF-1 and bFGF had
minimal additive effect in distance and number of chains per
neurosphere (P  0.05, Fig. 1 c and d). However, this combi-
nation did increase the thickness of the migratory chains when
compared with bFGF alone (Fig. 1 e and f ). Furthermore, it
enhanced the complexity of their branching, generating a fractal-
like pattern of chain migration. We quantified branching com-
plexity by measuring the fractal dimension (Df ) (15, 16) of
migrating neurospheres. The combination of SDF-1 and bFGF
induced an increase in Df (Fig. 1g). With a second measure of
branching complexity, the Sholl method (17), we similarly found
that SDF-1 and bFGF were additive in increasing the com-
plexity of radial chains emerging from neurospheres (Fig. 1h).
Interestingly, a fractal pattern of bifurcation (15) was generated,
a pattern resembling that in the rodent rostral migratory stream,
the route by which neural progenitors migrate in chains to the
olfactory bulb during normal development and neuronal turn-
over in adulthood (18) (Fig. 1g).
SDF-1 is the only chemokine that has but one cognate
receptor, namely CXC chemokine receptor 4 (CXCR4) (19). We
identified the constitutive expression of cxcr4 mRNA in hNSCs
by RNA protection assay (Fig. 2a, lanes 2 and 3) in two unrelated
hNSC lines, which have displayed injury-directed migration in
vivo (8, 9). Next, we demonstrated by FACS the expression of
CXCR4 protein in the intracellular compartment (Fig. 2b) and
on the surface (Fig. 2c) of undifferentiated hNSCs (8) (again
assaying multiple unrelated hNSC lines for validation). Confocal
microscopy of individual hNSCs confirmed in cultured hNSCs
the typical pattern of CXCR4 (20) (Fig. 6 f and g). These findings
were confirmed in human neurospheres double-labeled with a
different clone of anti-CXCR4 and vimentin (Fig. 2d). Rein-
forcing the notion that developmental mechanisms might be
recapitulated during injury-directed NSC migration, we deter-
Fig. 1. SDF-1 enhances proliferation and induces two forms of migration of hNSCs. (a) Proliferation assay showing significantly increased thymidine
incorporation by hNSCs after increasing SDF-1 dosage (cultured in triplicate): 10 ngml, P 0.03; 100 ngml, P 0.01; 1,000 ngml, P 0.0004 compared with
control (by Student’s t test.) (b Upper) Boyden chamber assay used for assaying migration. hNSCs are allowed to migrate into a fibronectin-coated membrane
(green), immersed in medium (orange) containing SDF-1 at different concentrations. The number of cells that cross the membrane and stain with crystal violet
(blue) reflects their migratory capacity. (b Lower) Quantification of hNSC migration as measured by optical density (absorbance) of crystal violet after 48 h. There
is a significant increase in migration in response to SDF-1: 500 ngml, P  0.02; 1 gml, P  0.05, compared with control (by Student’s t test). (c) Number of
chains migrating from neurospheres. SDF-1 alone significantly increases this number compared with no treatment (No T); P 0.05 ANOVA. (d) Mean maximal
distance migrated per chainneurosphere: SDF-1 alone had a significant effect compared with untreated (P 0.05 ANOVA), as did FGF (P 0.01) and FGF plus
SDF-1 (P 0.001). There was no significant difference between FGF and FGF plus SDF-1. (e and f ) Phase-contrast photomicrograph of neurosphere incubated
in FGF (20 ngml) alone (e) compared with neurosphere in FGF (20 ngml) plus SDF-1 (100 ngml) (f ), where there appears to be an increase in the number of
migrating cells and the complexity, branching, and thickness of migratory chains (arrows in f ). (g) Composite dark-field image of neurosphere in bFGF alone
compared with one treated with bFGF plus SDF-1. Such images were used to quantify the Df of chain migration. For bFGF-treated hNSCs, Df  1.2; for bFGF
plus SDF-1, Df 1.5 (Df values range from 1 to 2; values approaching 2 denote increasing complexity). The Df for hNSCs exposed to no additives is negligible.
(h) Quantification of branching complexity comparing bFGF-exposed with bFGF plus SDF-1-exposed hNSCs showing a significant increase in branching numbers
(P  0.003). (Branching for hNSCs exposed to no additives is negligible.)
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mined that CXCR4 expression is, in fact, also detected in situ in
nestin-expressing cells within the fetal mouse ventricular zone
(VZ), among nestin-expressing NSCs isolated from the fetal
murine VZ, and maintained in vitro, and in NSCs isolated and
cultured from the adult subventricular zone (Fig. 7, which is
published as supporting information on the PNAS web site).
Exposure of hNSCs to SDF-1 and the consequent induction
of CXCR4-mediated signaling triggered a series of intracellular
processes associated with fundamental aspects of survival, pro-
liferation, and, importantly, migration [a process that itself
involves multiple cooperative pathways and signals (11, 14, 18,
21)]. These steps, dissected in Fig. 2 e and f, include rapid and
sustained phosphorylation of p38MAPK kinase [implicated in
regulating cytokine-induced cell migration (22–24) (Fig. 2e)];
phosphorylation of the ribosomal S6 kinase (p90RSK) [implicated
in phosphorylation of cytoskeletal molecules involved in neurite
outgrowth (25, 26) (Fig. 2e)]; phosphorylation of c-Jun [a kinase
involved in migratory responses (27) (Fig. 2e)]; rapid activation
of extracellular response kinase (involved in proliferative re-
sponses), and rapid phosphorylation of paxilin [a scaffold mol-
ecule critical for migration (28) (Fig. 2f )].
Having established in vitro that SDF-1 activates molecular
pathways responsible for hNSC migration, we next ascertained
whether there was in vivo relevance by using a prototypical
pathological condition, HI injury. After induction of unilateral
HI inmouse brains (4), hNSCs were implanted at a distance from
the lesion (in periventricular areas, including on the contralat-
eral side) (Fig. 3 a–c). Although SDF-1 was expressed by
meningeal cells on both the ischemic and normal side (29) (Fig.
3 d and e, m), there was a profound up-regulation within the
injured parenchyma itself, which was populated by hNSCs that
had migrated there from their distant implantation site (Fig. 3
b and e) [and often differentiated into neurons (Fig. 3 f and g)].
hNSCs homed to areas of increased SDF-1 expression in the
injured cortex (Fig. 3h), where, often displaying a classic migra-
tory profile (Fig. 3i), they intertwined intimately with SDF-1-
expressing cells (Fig. 8a, which is published as supporting
information on the PNAS web site). We found a positive
correlation between the expression of SDF-1 per area and the
number of hNSCs present in the ischemic brain, the only source
of which had to have been via migration (r  0.6079, P 
0.0001) (Fig. 3 j and k). One of the sources of this increased
SDF-1 expression within the injured regions was the large
number of reactive astrocytes (coexpressing SDF-1 and glial
fibrillary acidic protein) (Fig. 3 m–o). On the uninjured side,
astrocytes (in a normal proportion) were nonreactive and did not
express SDF-1 (Fig. 3l). Up-regulation of SDF-1 production
within astrocytes was plausibly due to the inflammatory envi-
ronment that characterizes ischemic injury, because treatment of
astrocytes with IL-1 up-regulates their SDF-1 production
(30). An additional source of SDF-1 may have been blood
vessels (31) within the infarct, a region where endothelial cells
also up-regulated SDF-1 expression (Fig. 8b). To confirm the
role of SDF-1 in NSCmigration, we began to dissect the process
in vitro by culturing NSCs adjacent to organotypic cortical
explants (n  30) from ischemic (5 days postinfarct) and
uninjured murine hemispheres. NSCs isolated from an adult
murine subventricular zone and expressing emx2 (32), sox2 (33),
and nestin (Fig. 7), when cocultured as neurospheres with
ischemic cortical explants in coculture medium, elaborated
extensive robust networks of processes containing migrating
chains of nestin NSCs directed specifically toward and into the
explant, compared with nonischemic explants (Fig. 4 a, c–e) [or
to no explant in the presence of normal NSCs conditions where
Fig. 2. hNSCs express CXCR4, which activates intracellular molecular pathways upon SDF-1 stimulation. (a) Ribonuclease protection assay showing expression
of CXCR4 mRNA in two hNSC lines. Lane 1, yeast RNA (control); lane 2, hNSC clone H6 (6, 8, 9); lane 3, hNSC clone CC-2599 (43). L32, housekeeping gene as control
for equal loading. (b) FACS analysis of permeabilized cells revealing intracellular CXCR4 in the two above-mentioned hNSC lines. Black dotted histogram
represents results from the isotype control antibody; the red histogram represents staining with a monoclonal antibody against human CXCR4. (c) Membrane
expression of CXCR4 in three hNSC lines, H6, CC-2599, and HFB2050, compared with purified CD4 lymphocytes serving as a positive control. (d) Confocal
microscopic image of hNSCs dual-immunostained as neurospheres with antibodies to CXCR4 and vimentin. (e) Activation by SDF-1of hNSC intracellular signaling
pathways. hNSCs were exposed to SDF-1 (100 ngml) or to FGF plus EGF (20 ngml) followed by Western analysis for phosphorylation of p38MAPK, p90Rsk, c-Jun,
and extracellular response kinase at the indicated time points. The phosphorylated form (p-) is shown (Upper) for each molecule. ( f ) The rapid kinetics of paxilin
phosphorylation (p-Paxilin) with an increase after 2 and 5 min and a reduction thereafter.











extensions were nondirected and multiarrayed (Figs. 6a and 7 t
and u)]. The polarization and number of directed migratory
chains were significantly increased when confronted with isch-
emic explants (80% of neurospheres) relative to nonischemic
explants (only 12% of neurospheres) (Fig. 4 c and d). These
chain-migrating nestin NSCs expressed CXCR4 as they made
Fig. 3. hNSCs migrate to areas of SDF-1 up-regulation after stroke. (a) Mouse brain (coronal view) subjected to unilateral stroke. The infarct, largely a necrotic
cavity, is delineated by the blue area. Three areas per slide (boxes 1–3) were analyzed. Boxes 1 and 2 include the penumbra; box 3 is from the contralateral
uninjured cortex. The hNSCs depicted here were prelabeled ex vivo with chloromethylbenzamido derivate of 1,1-dioctadecyl-3,3,3,3-tetramethylindocarba-
cyanine perchlorate (DiI) before transplantation. (Inset) Red DiI hNSCs have homed to area 1. (b) DiI hNSCs (arrows), magnified (Inset), are seen migrating
across the corpus callosum (CC) from the contralateral intact hemisphere (site of implantation) to the infarcted hemisphere. (c) DiI fluorescence is specific to hNSCs
in ischemic brain (Left) and not seen at the Alexa Fluor 488 wavelength (Center) used for revealing SDF-1 immunoreactivity; merged (Right). (d) Normal
contralateral side (box 3) showing absence of DiI hNSCs (Left) and only expected meningeal (m) staining of SDF-1 (green) (Center); merge (Right). (e) DiI
hNSCs that have robustly homed to the penumbra (bottom), some of which have responded to this neurogenic niche by differentiating into neurons (identified
by an anti-human-specific NF antibody, an independent marker for hNSC-derived cells) ( f and g). SDF-1 immunoreactivity (green) is robust throughout the
penumbra. Boxed area in e is viewed at higher power as a merged image in hwhere a confocal microscopic 3D reconstruction shows the hNSCs (red) intertwined
intimately with the abundant SDF-1-expressing cells (green). The boxed area in h is shown at higher power in i via the red channel capturing a residual classic
elongated migratory profile of some DiI hNSCs. (j) High-resolution quantitative 2.5-dimensional imaging of hNSCs homing to SDF-1-enriched areas.
Topographical view of multiple areas (n  30) measured by confocal profile intensity. hNSC values are in gray scale; maximal SDF-1 expression is represented
in color. hNSCs colocalize with (home to) areas of high (Upper) but not low (Lower) SDF-1. (k) Correlation of SDF-1 expression in injured cortex and number
of migrating hNSCs (r  0.679; P  0.0001). (l upper) Contralateral normal parenchyma showing normal astrocytes (GFAP; red) with no SDF-1 (green)
coimmunostaining. (l lower) Infarcted side showing both an increase in GFAP-immunoreactive cells (red) with thick processes (suggestive of reactive astrocytes)
and an increase in SDF-1 (green) coimmunostaining. Merged images (yellow) suggest that the reactive astrocytes are coexpressing SDF-1. Colocalization of
GFAP (red) and SDF-1 (green) is confirmed by optical dissection and orthogonal reconstruction of the confocal image (o), showing intracellular localization of
SDF-1 in two representative reactive astrocytes (arrows).
18120  www.pnas.orgcgidoi10.1073pnas.0408258102 Imitola et al.
contact with the ischemic explant (Fig. 4b). Addition of a
monoclonal blocking antibody against CXCR4 (34, 35) reduced
to 14% the proportion of hNSCs migrating toward the ischemic
explant (Fig. 4e) and reduced the number and thickness of
bridges of migrating nestin chains compared with ischemic
explants incubated with an isotype control (Fig. 4f ).
Discussion
The expression of CXCR4 on hNSCs and an appropriate func-
tional response when exposed to its only ligand, SDF-1, not only
help establish their role in injury-mediated homing but likely
epitomize a paradigm wherein the many products of inflamma-
tion may collaborate to guide somatic stem cell behavior during
perturbations of an organ. The SDF-1–CXCR4 interaction
during injury likely recapitulates a developmental role for this
dyad in mammalian cerebrogenesis, as suggested by the CXCR4
expression of both nestin-expressing cells within the fetal ven-
tricular zone (VZ) in situ and NSCs cultured from the embryonic
VZ and adult subventricular zone (Fig. 7) (36, 37). CXCR4
presumably serves as a guidance molecule that is highly con-
served evolutionarily among mammalian NSCs, including in
humans.
Our data reinforce the pivotal role played by the SDF-1
CXCR4 pathway and likely other inf lammation-associated
mechanisms [including, for example, microglia (F.-J.M. and
E.Y.S., unpublished work)] in the migration of NSCs toward
regions of brain injury and degeneration. Although known to be
critical for hematopoietic homing to the bone marrow (35, 38),
the role that such a nonneural mechanism may play in the CNS
and that CNS-derived repair cells may be guided by nonneural
cues have been underappreciated. Indeed, in a broader sense,
inflammation may be viewed as playing more than its commonly
recognized adverse role in the CNS and other organs (1, 10, 39)
and as also providing stimuli that call in homeostasis-promoting
cells. Astrocytes and endothelial cells up-regulate SDF-1 after
injury (30, 31) and may work as catalysts and then as signposts
for mobilizing and directing quiescent NSCs via ligand–receptor
interactions. NSCs migrate to sources of SDF-1 in vivo and, in
response to this chemokine, self-organize into directedmigrating
chains of increasing complexity. The dynamic of SDF-1’s
interaction with CXCR4 appears to be at least one requirement
for NSC migration toward injury (40).
Our data provide not only a working model for one mecha-
nism underlying innate regenerative programs but also a unify-
ing explanation as to why NSCs appear to behave so similarly
when confronted with pathologies of disparate etiologies. The
inflammatory response that accompanies many CNS disease
processes, regardless of the underlying cause, appears to direct
NSCs (including those of human derivation). Intriguingly, prior
findings from our group suggest that once NSCs enter the injury
site, they begin to produce yet-to-be-identified antiinflammatory
molecules (4, 6, 41) [corroborated by others (42)]. The analogy,
Fig. 4. Migration in vitro of NSCs from subventricular zone toward explants from ischemic brain is mediated by SDF-1–CXCR4 interaction. (a) Mouse NSCs
(nestin) that migrate chain-like toward ischemic brain explants express CXCR4. The phase image is shown under fluorescence microscopy below it, dual
immunostained for nestin (green) and CXCR4 (red). (b) The area demarcated by the box in a, near the ischemic explant (asterisk), the border of which is indicated
by the dotted line, is magnified where the nestinNSCs (green) are noted to coexpress CXCR4 (red); dual-immunoreactive cells seen as yellow in merged image.
(c Left) Minimal chain migration of nestin cells to the contralateral noninjured explant correlating with an absence of SDF-1 in the explant, preserved only
in meninges (arrow). (c Right) Robust migration of nestin NSCs toward injured explant with an increase in polarization and number of chains (see Figs. 6 and
7). (d) Neurospheres confronted with explants (asterisk) from normal control hemispheres show no migration (Left), neurospheres confronted at the same
distance with explants from an ischemic hemisphere (asterisk) elaborate processes containing chains of migrating NSCs directed toward the explants (arrows)
(Center); these behaviors are abrogated in neurospheres confronted with an ischemic explant (asterisk) but treated with a purified blocking antibody to CXCR4
(10 g per explant) (Right). (e) Quantification of the percent of neurospheres with directed migration toward the explants. ( f) Quantification of the formation
of migratory chains toward the following explants: control, ischemic, or ischemic treated with anti-CXCR4 antibody. The latter condition reduces the number
of migratory chains (P  0.001).











therefore, is similar to a firefighter who is called to a blaze by the
flames but then douses them once he arrives. A better under-
standing of this complex dynamic may permit us to devise more
effective repair strategies by orchestrating the judicious use of
antiinflammatory agents that neutralize those aspects of inflam-
mation that are inimical to progenitor well being (1, 10, 39) while
enhancing and not negating those aspects that facilitate repair.
The following scenario might be envisioned (Fig. 5). As a
result of injury, surviving or invading glial cells (including
activated astrocytes and microglia), the first wave of responders
to injury, may produce chemoattractants such as SDF-1 that
may direct the migration of NSCs toward the ischemic core and
penumbra. Compromised vasculature, too, contributes to the
abundance of such chemokines within the infarcted parenchyma.
NSCs of exogenous or endogenous origin, by virtue of their
expression of chemokine receptors such as CXCR4, respond to
SDF-1 and similar chemoattractants that trigger the activation
and phosphorylation of scaffold and adapter molecules within
the NSCs and direct their migration in a chain-like fashion (even
along nonstereotypical migratory routes) toward the sources of
the chemokine, allowing them to home to the injured area and
to inhabit injury-induced stem cell niches (Fig. 5) harboring local
transiently expressed potentially reparative signals. Such a strat-
egy for prompting and directing regenerative processes may be
shared by many stem cell systems.
Note Added in Proof.While this paper was under review, Kelly et al. (45)
reported that hNSCs migrating to stroke lesions express CXCR4.
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Fig. 5. Model of inflammation-directed homing of NSCs toward pathology
(as modeled by SDF-1–CXCR4 interaction). As a result of injury, surviving or
invading glia, microglia, and endothelial cells, the first responders, may
produce chemoattractants (e.g., SDF-1) that direct NSCs toward the ischemic
core or penumbra (shaded area). NSCs of exogenous or endogenous origin
(arrows), by virtue of their expression of chemokine receptors (e.g., CXCR4),
respond to the chemokines that trigger the activation and phosphorylation of
scaffold and adapter molecules within the NSCs and direct NSC migration in a
chain-like fashion toward the source of the chemokines, allowing the NSCs to
home to the pathology, to produce antiinflammatoryantiscarring molecules,
and to engage local transiently expressed injury-induced signals.
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